Outcomes in Endometrial Cancer With High-Risk Tumor Features but No Muscle Wall Invasion
Looks back at outcomes in endometrial cancer that has not grown into the uterine muscle.
Plain-language title generated from the registry record
Registry title: Prognosis and Therapeutic Implications in Molecular High-Risk Non-Myoinvasive Endometrial Cancer
Key facts
- Where
- Barcelona, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study looks back at women over 18 with early endometrial cancer that has not grown into the womb muscle but has high-risk molecular features (p53-abnormal, or certain NSMP tumours), and who had lymph node staging.
- Age
- Over 18 years
- Sex
- Women only
- Disease stage
- Endometrial cancer with no invasion of the womb muscle (myometrium), cervix or adnexa. Survival analyses include only final stage IC (FIGO 2023). Tumour types: p53-abnormal, ER-negative NSMP, or high-grade NSMP.
- Earlier treatment
- Had surgery with lymph node staging: sentinel lymph node biopsy, with pelvic and/or para-aortic lymphadenectomy, or lymphadenectomy alone. Adjuvant treatment information must be complete.
- Biomarker or test result
- MMR and p53 status must be known, according to ESGO criteria. POLE mutation testing is not required.
Main reasons for not taking part
- Molecular profile not available
- No lymph node staging (no sentinel lymph node biopsy or lymphadenectomy)
- Inadequate follow-up
- Mismatch repair-deficient tumours
- POLE-ultramutated tumours, when identified
Read by machine on 9 November 2026.
Where in Spain
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital Universitari Vall d'Hebron Research Institute
- Trial code
- NCT07838207
- Record updated
- 24 September 2026
- Original description
This multicenter retrospective observational cohort study aims to evaluate the prognosis of patients with non-myoinvasive endometrial cancer harbouring high-risk molecular features by determining the rate of lymph node involvement (assessed by sentinel lymph node biopsy and/or lymphadenectomy), evaluating recurrence rates, progression-free survival (PFS) and overall survival (OS), and comparing oncological outcomes according to different adjuvant treatments.Read full original descriptionShow less
MyoNone: Prognosis and Therapeutic Implications in Molecular High-Risk Non-Myoinvasive Endometrial Cancer
This multicenter retrospective observational cohort study aims to evaluate the prognosis of patients with non-myoinvasive endometrial cancer harbouring high-risk molecular features by determining the rate of lymph node involvement (assessed by sentinel lymph node biopsy and/or lymphadenectomy), evaluating recurrence rates, progression-free survival (PFS) and overall survival (OS), and comparing oncological outcomes according to different adjuvant treatments.
The study will include patients with the following molecular subgroups of non-myoinvasive endometrial cancer:
* p53-abnormal tumours without myometrial invasion. * High-grade NSMP tumours without myometrial invasion. * ER-negative NSMP tumours without myometrial invasion.
Participating centres will be invited to retrospectively identify eligible patients diagnosed between 2010 and 2025 and enter anonymised data into a standardised REDCap database. Given the rarity of these clinical scenarios, international collaboration is essential to generate robust evidence that may help inform future clinical guidelines and optimize patient management.
Inclusion: Patients over 18 years old; Patients with:; 2.1. p53-abnormal (p53-abn) endometrial carcinoma. 2.2. ER-negative NSMP tumours. 2.3. High-grade NSMP tumours. POLE mutations assessment is not mandatory. MMR and p53 status is mandatory, according to ESGO criteria; In whom:; No myometrial invasion is present in the final surgical specimen (nor cervical or adnexal invasion); Tumours are identified by endometrial biopsy or hysteroscopic polypectomy with no residual tumour in the final surgical specimen (these cases will also be considered tumours without myometrial invasion); Patients who underwent nodal staging, either with pelvic sentinel lymph node biopsy, associated with pelvic and/or para-aortic lymphadenectomy, or staged by lymphadenectomy alone; 3.1. To assess the rate of lymph node involvement, we will analyze tumors with the previous molecular characteristics mentioned and no myometrial invasion, regardless of whether lymph node involvement is present. Stage IIIC tumours will not be excluded; cases will be selected based on the absence of myometrial infiltration in the final pathology specimen. 3.2. On the other hand, for the survival statistical analyses, only patients with a final stage IC (FIGO 2023) will be included.
Exclusion: Patients who do not meet the above inclusion criteria and who additionally present with the following conditions will be excluded:; Molecular profile not available; Absence of nodal staging (sentinel lymph node biopsy or lymphadenectomy); Inadequate follow-up; Mismatch repair-deficient tumors; POLE-ultramutated tumors, when identified; Incomplete information regarding adjuvant treatment; Presence of myometrial invasion.